Publikationen (447) Publikationen von EDUARDO DÍAZ-RUBIO GARCÍA

2024

  1. El cáncer, el gran reto de la medicina moderna: Importancia de estos diez últimos años y las perspectivas de futuro

    El Cronista del Estado Social y Democrático de Derecho, Núm. 112, pp. 52-57

  2. Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis

    European Journal of Cancer, Vol. 207

2023

  1. Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNÚ-1 and Phase II VISNÚ-2 Randomized Trials

    Clinical Colorectal Cancer, Vol. 22, Núm. 2, pp. 222-230

  2. Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 21, pp. 3663-3669

  3. Evaluation of Intratumoral Response Heterogeneity in Metastatic Colorectal Cancer and Its Impact on Patient Overall Survival: Findings from 10,551 Patients in the ARCAD Database

    Cancers, Vol. 15, Núm. 16

  4. Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trials

    European Journal of Cancer, Vol. 190

  5. Results of a Phase II Trial Testing the Resensitization With Trabectedin in Platinum-resistant Ovarian Cancer

    Cancer Diagnosis and Prognosis, Vol. 3, Núm. 3, pp. 302-310

2022

  1. Association of miR-21 and miR-335 to microsatellite instability and prognosis in stage III colorectal cancer

    Cancer Biomarkers, Vol. 34, Núm. 2, pp. 201-210

  2. Molecular Classification of Colorectal Cancer by microRNA Profiling: Correlation with the Consensus Molecular Subtypes (CMS) and Validation of miR-30b Targets

    Cancers, Vol. 14, Núm. 21

  3. Real Academia Nacional de Medicina de España

    Las Reales Academias Nacionales en Madrid (Instituto de Estudios Madrileños), pp. 157

  4. Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

    European Journal of Surgical Oncology, Vol. 48, Núm. 5, pp. 1123-1132

2021

  1. Behavioural and structural interventions in cancer prevention: towards the 2030 SDG horizon

    Molecular Oncology, Vol. 15, Núm. 3, pp. 801-808

  2. First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis

    Drugs and Aging, Vol. 38, Núm. 3, pp. 219-231

  3. Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis

    Therapeutic Advances in Medical Oncology, Vol. 13

  4. Implementation of the Quality Oncology Practice Initiative Program in Spain: First Results and Implications

    JCO oncology practice, Vol. 17, Núm. 8, pp. e1162-e1169

  5. Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study

    ESMO open, Vol. 6, Núm. 2, pp. 100062

  6. Management and perception of therapeutic adherence of breakthrough cancer pain by oncologists in Spain

    Revista de la Sociedad Espanola del Dolor, Vol. 28, pp. 19-26

  7. Treatment breaks in first line treatment of advanced colorectal cancer: An individual patient data meta-analysis

    Cancer Treatment Reviews, Vol. 99

2020

  1. Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected

    Clinical Colorectal Cancer, Vol. 19, Núm. 3, pp. e110-e116

  2. Correction: Tumour location and efficacy of first-line EGFR inhibitors in KRAS/RAS wild-type metastatic colorectal cancer: Retrospective analyses of two phase II randomised Spanish TTD trials (ESMO Open (2019) 4 (e000599) DOI: 10.1136/esmoopen-2019-000599

    ESMO Open